Page 47 - Academic Press Encyclopedia of Physical Science and Technology 3rd InOrganic Chemistry
P. 47

P1: ZBU Final Pages
 Encyclopedia of Physical Science and Technology  EN002F-55  May 22, 2001  21:6







              Bioinorganic Chemistry                                                                      135

                                    ˚
              The inside “diameter” is 75 A and can accommodate up to
              4500 iron atoms. The mechanism by which this iron core
              is formed is under investigation. One interesting problem
              is the introduction of iron atoms into the interior of the
              ferritin. There are two channels that might serve as pas-
              sageways for the iron: a fourfold and a threefold chan-
              nel. Hydrophobic residues line the interior of the fourfold
              channel. This channel would serve as a poor entrance for
              charged ions such as Fe(II) or Fe(III). However, these hy-
              drophobic interactions may play a significant role in the
              stabilization of the assembly, helping to satisfy step 1 in
              the formation of biominerals—formation of a supramolec-
              ular construct. The threefold channel is lined by several
              hydrophilic residues and is the more likely candidate for
              Fe passage. Recently, dimeric Fe(II)-binding sites in the
              protein shell have been investigated as possible sites of
              initial introduction of iron into ferritin. At these sites,
              Fe(II) is oxidized to Fe(III) by oxygen, forming an oxo-
              or hydroxo-bridged Fe(III) that migrates into the interior
              of ferritin for storage.
                Once the iron is inside the sphere, a site of mineral nu-
              cleation is located—step 2 in the biomineralization pro-
              cess. Although the site(s) of nucleation are not known,
              the walls are lined with carboxylic acids from aspartate
              and glutamate residues. These are the probable sites of  FIGURE 11 Examples of inorganic pharmaceuticals.
              nucleation. After nucleation, the mineral begins to form.
              The shape is controlled by the protein shell. Studies of
              the resulting mineral are consistent with octahedrally co-
                                                                the leading drugs for cancer treatment; (3) photophysi-
              ordinated iron(III) ions joined by bridging oxide and/or
                                                                cal properties, for maladies ranging from psoriasis to can-
              hydroxide ions. A mineral termed ferrihydrite has a sim-
                                                                cer; (4) properties of new drugs to treat diabetes with-
              ilar postulated structure. Because ferritin is used for iron
                                                                out using insulin; (5) radioactivity for use in imaging
              storage agents, the supramolecular structures described in
                                                                agents; and (6) paramagnetism for magnetic resonance
              step 4 of Section III.B are not formed.
                                                                imaging (MRI) agents. Examples of each of these proper-
                                                                ties is given below and in Fig. 11. Some of the complexes
                                                                are already in clinical use, while others are in clinical
              IV. MEDICAL USES FOR                              trials.
                 INORGANIC COMPOUNDS                              In addition to the use of inorganic compounds to treat
                                                                illnesses, treatments for genetic defects in inorganic ion
              A. Overview                                       metabolism and environmental exposure to toxic ions are
                                                                also discussed. The majority of these disfunctions are
              Inorganic compounds have been used for centuries for
                                                                treated with some sort of chelation therapy (for overex-
              their pharmacological properties. Recently, however, the
                                                                posure) or metal substitutes (for underexposure). These
              understanding of how inorganic compounds interact with
                                                                therapies are briefly discussed below.
              biological molecules has enabled chemists, biologists, and
              physicians to synthesize and test the medicinal quali-
              ties of these compounds in a more systematic way. The
                                                                B. Redox Chemistry in Medicine
              unique properties of inorganic compounds enable new
                                                                                         −
              mechanisms to be exploited in the treatment of many  The free radical superoxide, O , reacts with nitric ox-
                                                                                         2
              diseases.                                         ide, NO, to produce damaging peroxinitrite, OONO .
                                                                                                            −
                Some of the unique properties being explored include  This process has been postulated to be a mediator of
              the following: (1) physiologically relevant redox poten-  ischemia-reperfusion injury as well as inflammatory and
              tials for cancer drugs that cleave DNA and drugs that  vascular diseases. Superoxide dismutases (SODs), en-
              remove harmful oxygen radicals; (2) ligand exchange  zymesdiscussedpreviously,areresponsibleforconverting
              for many anticancer drugs, including cisplatin, one of  superoxide to hydrogen peroxide and oxygen. SODs are
   42   43   44   45   46   47   48   49   50   51   52